Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Dec;59(4):641-649.
doi: 10.20471/acc.2020.59.04.10.

Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control

Affiliations
Observational Study

Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control

Hrvoje Pintarić et al. Acta Clin Croat. 2020 Dec.

Abstract

Our observational study evaluated current management of elevated low-density lipoprotein cholesterol (LDL-C) in adult secondary prevention patients (all very high risk (VHR) by European guidelines) attending specialist clinics across Croatia. Data were collected retrospectively from patient records for the preceding 12 months. The subset judged to be at extreme risk (ER; American Association of Clinical Endocrinologists (AACE) criteria; n=48) were compared with the remaining patients (VHR group; n=41). All patients were receiving statins (75.6% VHR/81.3% ER at high-intensity), with only a minority receiving concomitant lipid-lowering treatment (7.3% VHR/16.7% ER). Median (Q1, Q3) LDL-C levels at the last visit were 1.9 (1.6, 2.4) mmol/L for VHR and 2.1 (1.5, 3.1) mmol/L for ER, with only 41.5% (95% CI 26.3-57.9) of VHR patients and 27.1% (15.3-41.9) of ER patients attaining their LDL-C targets (<1.8 mmol/L and <1.42 mmol/L, respectively). Thus, we found that a substantial proportion of VHR and ER secondary prevention patients being treated across Croatia had LDL-C levels exceeding the targets recommended in the European and newer AACE guidelines, but not all were receiving high-intensity statins. Identification of ER patients and their lipid patterns may help optimize usage of high-intensity statin treatment, alone or along with newer treatments, for better control of elevated LDL-C.

Keywords: Extreme risk patients; High-risk patients; Hyperlipidemia; Secondary prevention; Very high-risk patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Median LDL-C levels (mmol/L) at first and last visit of the observation period according to cardiovascular risk category (bars indicate Q1 and Q3).
Fig. 2
Fig. 2
Achievement of ESC/EAS and AACE-defined LDL-C targets by cardiovascular risk category at any time during the observation period. Results shown as percentage of patients in category with two-sided 95% confidence intervals in brackets.

Similar articles

Cited by

References

    1. World Health Organization. Cardiovascular diseases. Fact sheet. Updated May 2017. http://www.who.int/mediacentre/factsheets/fs317/en/ In. 2017.
    1. Kannel WB. The Framingham Study: an epidemiological investigation of cardiovascular disease, Section 30. Some characteristics related to the incidence of cardiovascular disease and death: The Framingham Study. 18-year follow-up.Washington, D.C., Department of Health, Education, and Welfare, Publication No. (NIH) 74-599, 1974.
    1. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C–77C. 10.1016/S0002-9149(99)80474-3 - DOI - PubMed
    1. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med. 1979;90:85–91. 10.7326/0003-4819-90-1-85 - DOI - PubMed
    1. Cholesterol Treatment Trialists Collaboration . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. 10.1016/S0140-6736(10)61350-5 - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources